Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

June 15, 2023

Study Completion Date

December 30, 2023

Conditions
Post Acute COVID-19 SyndromeLong COVIDLong Covid19COVID-19 RecurrentPost-Acute COVID-19Post-Acute COVID-19 InfectionSARS-CoV2 InfectionPost Acute Sequelae of COVID-19DysautonomiaDysautonomia Like DisorderDysautonomia Orthostatic Hypotension SyndromePost COVID-19 ConditionPost-COVID SyndromePost COVID-19 Condition, UnspecifiedPost-COVID-19 Syndrome
Interventions
DRUG

stellate ganglion block with 0.5% bupivacaine

"The stellate ganglion block is being done on both sides of the neck. The stellate ganglion block will be performed on the right side at the first visit. The procedure will be repeated on the left side one week after the first injection.~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in the labeling for the drug. Similar to a phase 1 clinical trial, the main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms. As a general rule, phase 1 studies require a low number of patients, typically 12-20 subjects. There is considerable uncertainty regarding long COVID as a disease state, so data from even small numbers of patients in a well-designed clinical trial will make steps towards reducing that uncertainty."

Trial Locations (1)

10014

Hudson Medical, New York

All Listed Sponsors
lead

Jonathann Kuo, MD

OTHER